SCHOLAR ROCK HOLDING CORP
SRRKNASDAQTrading Snapshot
- Day Range
- $43.52 – $45.19
- 52-Week Range
- $27.07 – $61.76
- Volume (shares)
- 330,833.218
- Avg Volume (shares)
- —
- Shares Outstanding
- 121.8M
- Next Earnings
- 2026-11-10
Fundamentals Snapshot
- Annual Revenue
- —
- Last Q Revenue
- —
- P/E Ratio
- —
- P/S Ratio
- 109.5x
- EPS (TTM)
- $-3.30
- Dividend Yield
- —
- Dilution (1yr)
- +14.9%
SCHOLAR ROCK HOLDING CORP
SRRK
StockOtter · stockotter.spaceAbout SCHOLAR ROCK HOLDING CORP
Scholar Rock Holding Corporation is a biopharmaceutical firm dedicated to discovering and advancing treatments for severe medical conditions by targeting the crucial role of protein growth factor signaling. Their lead therapeutic candidate, Apitegromab, an agent designed to inhibit the activation of latent myostatin, has successfully concluded Phase 3 clinical trials for spinal muscular atrophy (SMA). Another key program, SRK-181, is currently undergoing Phase 1 clinical assessment for tackling cancers that exhibit resistance to established checkpoint inhibitor treatments, including anti-PD-1 or anti-PD-L1 antibody therapies. Beyond these, the company cultivates a robust pipeline of innovative potential therapies, aiming to significantly improve the lives of individuals grappling with various severe ailments, such as neurological muscle conditions, malignancies, and fibrotic disorders. In a strategic partnership, Scholar Rock is collaborating with Gilead Sciences, Inc. to identify and develop targeted inhibitors of transforming growth factor beta (TGF-beta) activation, specifically for addressing fibrotic diseases. Established in 2012, Scholar Rock Holding Corporation operates from its headquarters in Cambridge, Massachusetts.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
Analyst Ratings
ⓘLatest News & Updates
Scholar Rock to Report Third Quarter 2026 Financial Results on November 10, 2026
Scholar Rock (NASDAQ: SRRK) today announced that it will report third quarter 2026 financial results on Tuesday, November 10, 2026, before the financial markets
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK; the “Company”) today announced that the Company granted inducement equity awards covering an aggregate of 61,020 shares of its common stock to seven newly hi
Scholar Rock Resubmits Apitegromab Marketing Authorisation Application (MAA) to European Medicines Agency (EMA) for Treatment of Children and Adults with Spinal Muscular Atrophy (SMA)
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of patients with rare, severe, and debilitating neuromuscular diseases by applying its l
Scholar Rock (NASDAQ:SRRK) Stock Falls 5.1% – Here’s What Happened
Shares of Scholar Rock Holding Corporation (NASDAQ: SRRK - Get Free Report) traded down 5.1% on Monday. The stock traded as low as $44.59 and last traded at $44.4380. Approximately 908,652 shares were traded during mid-d
Kuehn Law Encourages Investors of Scholar Rock Holding Corp to Contact Law Firm
NEW YORK, Sept. 30, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Scholar Rock Holding Corp (NASDAQ: SRRK) breached their fiduciary d
Scholar Rock Holding Corporation $SRRK Shares Bought by Engineers Gate Manager LP
Engineers Gate Manager LP lifted its stake in shares of Scholar Rock Holding Corporation (NASDAQ: SRRK) by 211.3% during the second quarter, according to the company in its most recent disclosure with the Securities and